Drug intelligence / Profile preview

LY341770

Development stage: Preclinical
Lead developer: Eli Lilly
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules

Overview

LY341770 is an experimental small molecule antifolate developed as an inhibitor of thymidylate synthase. It belongs to the class of pyrrolo(2,3-d)pyrimidine-based antifolates and was designed to circumvent drug resistance by forming covalent closed inhibitory complexes with both human and Escherichia coli thymidylate synthases. The compound has been studied structurally in complex with its target enzyme, demonstrating specific interactions that increase its affinity when polyglutamylated. Its primary research focus has been on cancer and drug resistance related to dTMP synthesis[1][4][9].

Targets

TS (Thymidylate synthase)

Beyond the preview

Go deeper on LY341770.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY341770.

Explore the full profile